HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The role of adjuvant chemotherapy for lymph node-positive upper tract urothelial carcinoma following radical nephroureterectomy: a retrospective study.

AbstractOBJECTIVE:
To evaluate the effect of adjuvant chemotherapy (AC) on mortality after radical nephroureterectomy (RNU) for upper tract urothelial carcinoma (UTUC) with positive lymph nodes (LNs) and to identify patient subgroups that are most likely to benefit from AC.
PATIENTS AND METHODS:
We retrospectively analysed data of 263 patients with LN-positive UTUC, who underwent full surgical resection. In all, 107 patients (41%) received three to six cycles of AC, while 156 (59.3%) were treated with RNU alone. UTUC-related mortality was evaluated using competing-risks regression models.
RESULTS:
In all patients (T(all) N+), administration of AC had no significant impact on UTUC-related mortality on univariable (P = 0.49) and multivariable (P = 0.11) analysis. Further stratified analyses showed that only N+ patients with pT3-4 disease benefited from AC. In this subgroup, AC reduced UTUC-related mortality by 34% (P = 0.019). The absolute difference in mortality was 10% after the first year and increased to 23% after 5 years. On multivariable analysis, administration of AC was associated with significantly reduced UTUC-related mortality (subhazard ratio 0.67, P = 0.022). Limitations of this study are the retrospective non-randomised design, selection bias, absence of a central pathological review and different AC protocols.
CONCLUSIONS:
AC seems to reduce mortality in patients with pT3-4 LN-positive UTUC after RNU. This subgroup of LN-positive patients could serve as target population for an AC prospective randomised trial.
AuthorsIlaria Lucca, Wassim Kassouf, Anil Kapoor, Adrian Fairey, Ricardo A Rendon, Jonathan I Izawa, Peter C Black, Harun Fajkovic, Christian Seitz, Mesut Remzi, Peter Nyirády, Morgan Rouprêt, Vitaly Margulis, Yair Lotan, Michela de Martino, Sebastian L Hofbauer, Pierre I Karakiewicz, Alberto Briganti, Giacomo Novara, Shahrokh F Shariat, Tobias Klatte
JournalBJU international (BJU Int) Vol. 116 Issue 1 Pg. 72-8 (Jul 2015) ISSN: 1464-410X [Electronic] England
PMID24825476 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Copyright© 2014 The Authors BJU International © 2014 BJU International Published by John Wiley & Sons Ltd.
Chemical References
  • Antineoplastic Agents
Topics
  • Aged
  • Antineoplastic Agents (administration & dosage)
  • Chemotherapy, Adjuvant (methods)
  • Drug Therapy, Combination (methods)
  • Female
  • Humans
  • Lymph Nodes (pathology)
  • Male
  • Middle Aged
  • Retrospective Studies
  • Survival Rate
  • Treatment Outcome
  • Urologic Neoplasms (drug therapy, mortality, surgery)
  • Urothelium (pathology, surgery)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: